methsuximide
Enable an agent to recognise methsuximide, assess the identity and fitness of a material sample, and determine which handling or pharmaceutical-use decisions its evidence supports.
Bundle → Layer → Finding → Questions Filled
6 bundles · 11 layers · 17 findings · 32 questions
Methsuximide identity Establishes which chemical entity the registry entry denotes.
Molecular boundary
Defines the parent structure and separates neighbouring chemical entities.
Parent structure match
Record structural identity evidence and the reference against which the candidate material was compared.
- Which authoritative structure defines methsuximide, including any specified stereochemical composition? definition
- Which analytical observations distinguish this sample from other succinimides and the N-desmethyl derivative? measurement
Identifier reconciliation
Connects the registered substance to external chemical records without importing product identity.
Authority-linked identifiers
Maintain verified identifiers and candidate synonyms with their source and identity scope.
- Which CAS, PubChem, UNII and applicable EC records resolve to the same methsuximide structure? provenance
- Does each encountered name denote methsuximide itself, a containing medicine or a different chemical entity? boundary
Methsuximide material quality Describes the composition and qualification of a particular methsuximide lot.
Assay and related substances
Separates parent content from impurities and other sample components.
Selective composition evidence
Require methods that quantify methsuximide with demonstrated selectivity for relevant accompanying compounds.
- What is the methsuximide mass fraction, on what reporting basis, and with what measurement uncertainty? measurement
- Which related substances, residual solvents and water measurements are required by the applicable specification? definition
- Can the assay resolve methsuximide from the impurities actually encountered in this lot? measurement
Grade and lot disposition
Connects lot evidence to a qualified material use.
Supported grade claim
Treat grade and release status as documented conclusions rather than consequences of a supplier's substance name.
- Which dated specification and certificate support this lot's claimed methsuximide grade? provenance
- Does the evidence permit the proposed analytical or manufacturing use, or require quarantine or retesting? action
Methsuximide physical condition Records condition-dependent properties and changes during storage or preparation.
Phase and preparation properties
Qualifies thermal and solubility observations with their experimental conditions.
Qualified property measurements
Record measured methsuximide properties with sample composition, methods and conditions.
- What phase and melting interval does the qualified methsuximide sample exhibit, and is decomposition observed? measurement
- What solubility is demonstrated in the intended preparation medium at the stated temperature and pH? measurement
- Is any reported boiling point experimental, estimated or invalidated by decomposition? provenance
Storage and change
Tracks whether handling history compromises the lot's qualified condition.
Stability-supported disposition
Base storage limits and retest decisions on evidence applicable to the actual methsuximide material and container.
- Which stability data support temperature, moisture and light controls for this bulk material or prepared solution? provenance
- After an excursion, which methsuximide assay or degradation measurements determine whether the material remains usable? action
Methsuximide pharmaceutical relations Connects the substance to medicines and biological transformation while retaining separate entity boundaries.
Ingredient to medicine
Locates therapeutic claims on the appropriate medicine and jurisdiction.
Label-scoped use
The cited US Celontin label identifies use for absence seizures refractory to other drugs; represent this as a product-label relationship. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74)
- Which dated medicine label supports the indication associated with this methsuximide-containing product? provenance
- Which strength, formulation and use restrictions belong to the linked medicine rather than to bulk methsuximide? boundary
Parent and metabolite evidence
Separates administered chemical identity from analytes observed after administration.
Analyte-specific interpretation
Attach biological measurements to their exact parent or metabolite analyte, matrix and sampling context.
- Does the result quantify methsuximide, N-desmethylmethsuximide or a combined analytical signal? definition
- What matrix, sampling time, units and assay selectivity qualify the result? measurement
- Which primary evidence establishes the metabolite's activity and persistence relative to methsuximide? provenance
Methsuximide hazards and permissions Supports evidence-based handling and distinguishes substance constraints from medicine regulation.
Bulk handling evidence
Establishes controls for the actual methsuximide material and operation.
Material-specific exposure controls
Use applicable hazard records and exposure assessments for weighing, transfer, spills and disposal.
- Which dated SDS and jurisdictional GHS assessment apply to this methsuximide grade and physical form? provenance
- Is there an authoritative occupational exposure limit, or only a supplier or internal control limit? definition
- Which documented controls govern this quantity and operation, including spill collection and disposal? action
Clinical and regulatory boundaries
Links restrictions to their source, subject and jurisdiction.
Restriction scope
The cited label contraindicates use in patients with succinimide hypersensitivity; retain this as a clinical restriction separate from workplace classification. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74)
- Which clinical warnings and interaction records should an agent retrieve before passing methsuximide information into a treatment workflow? action
- Does a cited restriction govern the chemical substance, a pharmaceutical ingredient lot or a particular marketed medicine? boundary
- Which authority and effective date support the applicable supply or use restriction? provenance
Evidence and external alignment What the world already says about this thing, gathered so the model can be checked against it.
Reported evidence
Findings from the breadth pass, kept separate from the structural claims.
Check these first
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these check these first hold for the sense of methsuximide this model covers, and on what evidence? provenance
Identifiers and schemes
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these identifiers and schemes hold for the sense of methsuximide this model covers, and on what evidence? provenance
Real-world use
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these real-world use hold for the sense of methsuximide this model covers, and on what evidence? provenance
Typical measurements
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these typical measurements hold for the sense of methsuximide this model covers, and on what evidence? provenance
Failure modes and hazards
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these failure modes and hazards hold for the sense of methsuximide this model covers, and on what evidence? provenance
Regional variation
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these regional variation hold for the sense of methsuximide this model covers, and on what evidence? provenance
Neighbouring kinds and how to tell them apart
Recalled without web access and unsourced; every item is a lead to verify.
- Which of these neighbouring kinds and how to tell them apart hold for the sense of methsuximide this model covers, and on what evidence? provenance
Classifiers Filled
- Family
- Thing Registry
- Category
- Physical world and living systems
- Entry kind
- thing
- Plane
- PHY
- Domain
- PHY.MAT
- Other names and narrower kinds
- (3S)-1,3-Dimethyl-3-phenylpyrrolidine-2,5-dione
What it is Filled
Methsuximide is a synthetic succinimide anticonvulsant whose antiseizure activity is substantially mediated by its active metabolite, N-desmethylmethsuximide, and which is used for absence seizures resistant to other medicines.
In scope
- Molecular identity and authoritative substance identifiers for methsuximide
- Sample grade, assay, impurities and analytical identity evidence
- Physical form, measured properties and storage-dependent condition
- Relationships to methsuximide-containing medicines and metabolic products
- Substance handling hazards and jurisdiction-specific constraints
Out of scope
- Finished capsule formulations, excipients, packaging and product authorisations
- Patient diagnosis, prescribing, dose adjustment and individual treatment outcomes
- Independent models of N-desmethylmethsuximide and other succinimides
- Manufacturing equipment and complete synthesis procedures
- General models of epilepsy and absence seizures
Why it exists Filled
Enable an agent to recognise methsuximide, assess the identity and fitness of a material sample, and determine which handling or pharmaceutical-use decisions its evidence supports.
Distinguishing features Filled
- Require molecular connectivity consistent with N,2-dimethyl-2-phenylsuccinimide; a succinimide class label alone cannot establish identity. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74)
- Check the formula C12H13NO2 and PubChem CID 6476 together with a structure-specific analytical result; formula alone cannot distinguish isomers. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Methsuximide)
- Distinguish the parent compound from N-desmethylmethsuximide when assigning analytical results; the label explicitly distinguishes this metabolite in poisoning assessment. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74)
- Treat Celontin as a linked medicine containing methsuximide, rather than identifying the capsule and its excipients as the pure substance. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=64a6ee88-c6b1-4e13-8208-b6772ef65a74)
What robots and AI may and may not do Filled
Must not
- Recommend, dose or adjust methsuximide for a particular patient.
- Advise stopping an anticonvulsant suddenly.
- Downplay warnings on mood changes, blood disorders or pregnancy.
- Help anyone obtain it without a prescription.
Only with a human decision
- Any decision to start, stop or change an antiseizure medicine.
May
- Describe methsuximide, its use in absence seizures and its warnings from official drug information.
- Remind patients to keep taking anticonvulsants as prescribed and to talk to their doctor before changes.
- Track stock and expiry in a pharmacy the agent is authorized to manage.
Moral aspects Filled
- Stopping antiseizure medicines abruptly can trigger dangerous seizures.
- People with epilepsy face stigma and need accurate, respectful information.
Who is affected
- People with epilepsy
- Families and carers
- Prescribers
Owners Filled
Steward
The prescribing clinician answers for each use; medicines regulators authorize the product.
Master systems
- National medicines registers
Links to other meta-models Filled
parent
- Q11173 - registry parent class
What else AI and robots need to interact with it Filled
Identity and identifiers required Filled
- Vercy registry: vr.tr.methsuximide
- Wikidata: Q906414 (https://www.wikidata.org/wiki/Q906414)
Direct properties required Filled
- Molecular identity agreement: confirmed | provisional | conflicting | untested; structure and analytical evidence required
- Substance identifier mapping: Registry id, CAS number, PubChem CID, UNII and EC number where verified, each linked to its authority
- Methsuximide assay: % mass fraction, with as-is or dry basis, method and uncertainty
- Related substances and residuals: % or mg/kg by named analyte; method, detection limit and acceptance specification
- Material grade: reference standard | research reagent | pharmaceutical ingredient | unspecified; supporting specification
- Physical form and thermal behaviour: Observed phase; melting interval in °C; thermal method, pressure and decomposition observation
- Solubility under stated conditions: mg/mL or mol/L, with solvent, temperature, pH where relevant and equilibration method
- Sample disposition: quarantined | released for specified use | retest required | rejected
- Parent-metabolite relationship: Named metabolite, transformation evidence and analyte-specific biological measurements
- Applicable hazard and regulatory record: Dated SDS, GHS assessment, exposure-limit authority and jurisdiction-specific ingredient or product record
Recognition required Filled
- A material label naming methsuximide or mesuximide provides a documentary identification cue that requires supporting analytical evidence.
- The molecular formula C12H13NO2 on an accompanying label or certificate helps distinguish the stated substance from other succinimide anticonvulsants.
- The pure substance is described as a white crystalline powder, an appearance shared by many compounds and insufficient to confirm identity.
Capabilities and actions required Filled
- Reconcile a supplier-labelled methsuximide sample with authoritative identity records and reference analyses.
- Compare assay and impurity results with the specification required for a proposed use.
- Select documented analytical preparation and storage conditions appropriate to the material form.
- Link a medicine to its methsuximide ingredient while preserving product-specific strength and excipients.
- Separate parent and metabolite evidence when reviewing biological analyses.
- Release, quarantine or request retesting of a sample using explicit evidence and decision authority.
Hazards and failure modes required Filled
- Can cause drowsiness, blood disorders and changes in mood or behaviour.
- Sudden withdrawal can provoke seizures.
Standards and interfaces required Filled
- The Anatomical Therapeutic Chemical classification issued by the WHO Collaborating Centre for Drug Statistics Methodology assigns methsuximide, listed as mesuximide, code N03AD03.
- The Federal Food, Drug, and Cosmetic Act, enacted by the United States Congress and administered by the Food and Drug Administration, governs its medicinal products in the United States.
Context of use required Filled
- Methsuximide is encountered as a pharmaceutical active substance and in prescription medicines for absence seizures resistant to other medicines.
- It is also encountered in pharmaceutical quality testing and studies of its active metabolite.
Sources Filled
- Wikidata item Q906414: methsuximide - identity and sense of the item
- Wikipedia: Mesuximide - general description of the item
Open questions
- Which authoritative records establish the CAS number, applicable EC identifier, accepted synonyms and stereochemical scope of this registry entry?
- Which current compendial or validated specifications define methsuximide assay, related-substance limits and pharmaceutical ingredient qualification?
- What experimentally supported melting, solubility, thermal decomposition and storage-stability data apply to identified bulk forms and prepared solutions?
- Which jurisdiction-specific GHS classifications and occupational exposure limits, if any, are supported for bulk methsuximide?
- Which primary studies establish parent-versus-metabolite activity, persistence and analytical interpretation, and where does that evidence remain uncertain?
Machine files
Provenance
thing registry research (pass 2) · unreviewed
Built from: models/things/publications/thing-q906414/spec.json